A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

Nimish Thakral; Hailemichael Desalegn; Luis Antonio Diaz; Daniel Cabrera; Rohit Loomba; Marco Arrese; Juan Pablo Arab

doi:10.1055/a-2364-2928

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2024; 44(03): 273-286
DOI: 10.1055/a-2364-2928

Review Article

A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

Nimish Thakral

¹Division of Gastroenterology and Hepatology, University of Kentucky, Lexington, Kentucky

,

Hailemichael Desalegn

²Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University, London, Ontario, Canada

,

Luis Antonio Diaz

³Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

,

Daniel Cabrera

⁴Centro de Investigación e Innovación Biomédica (CiiB), Universidad de los Andes, Santiago, Chile

⁵Escuela de Medicina, Facultad de Ciencias Medicas, Universidad Bernardo O'Higgins, Santiago, Chile

,

Rohit Loomba

⁶Division of Gastroenterology and Hepatology, MASLD Research Center, University of California San Diego, San Diego, California

,

Marco Arrese

³Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

,

Juan Pablo Arab

³Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

⁷Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia

› Author Affiliations

Abstract

The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.

Keywords

biomarkers - steatosis - MASLD - cirrhosis - precision medicine

Full Text

References

References
1 Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024; 73 (04) 691-702
2 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77 (04) 1335-1347
3 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
4 Le MH, Yeo YH, Zou B. et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach. Clin Mol Hepatol 2022; 28 (04) 841-850
5 Younossi ZM, Golabi P, Paik J. et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int 2024; 44: 1061-1070 Wiley Online Library. Accessed June 23, 2024 at: https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.15852
6 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78 (06) 1966-1986
7 Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol 2024; 80 (02) e51-e52
8 U.S. Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. Published March 15, 2024. Accessed June 23, 2024 at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
9 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease?. Adv Nutr 2020; 11 (06) 1696-1711
10 Radhakrishnan S, Yeung SF, Ke JY, Antunes MM, Pellizzon MA. Considerations when choosing high-fat, high-fructose, and high-cholesterol diets to induce experimental nonalcoholic fatty liver disease in laboratory animal models. Curr Dev Nutr 2021; 5 (12) nzab138
11 Thiagarajan P, Aithal GP. Drug development for nonalcoholic fatty liver disease: landscape and challenges. J Clin Exp Hepatol 2019; 9 (04) 515-521
12 Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158 (07) 1999-2014.e1
13 Delpierre C, Lefèvre T. Precision and personalized medicine: what their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol 2023; 8: 1112159
14 Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol 2020; 72 (06) 1196-1209
15 Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 2020; 158 (07) 1865-1880.e1
16 Salari N, Darvishi N, Mansouri K. et al. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. BMC Endocr Disord 2021; 21 (01) 125
17 Rosso C, Caviglia GP, Birolo G. et al. Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2023; 21 (13) 3314-3321.e3
18 Pappachan J, Fouda S. Metabolic-Associated Fatty Liver Disease, An Issue of Endocrinology and Metabolism Clinics of North America; 2023. Accessed June 23, 2024 at: https://shop.elsevier.com/books/metabolic-associated-fatty-liver-disease-an-issue-of-endocrinology-and-metabolism-clinics-of-north-america/pappachan/978-0-443-18407-9
19 Krawczyk M, Stokes CS, Romeo S, Lammert F. HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol 2015; 62 (04) 980-981
20 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity. World J Hepatol 2021; 13 (11) 1584-1610
21 Lonardo A, Ballestri S, Targher G. “Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis 2017; 257: 253-255
22 Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: new therapeutic insights from genetics and systems biology. Clin Mol Hepatol 2020; 26 (04) 461-475
23 Emdin CA, Haas M, Ajmera V. et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology 2021; 160 (05) 1620-1633.e13
24 Romeo S, Jamialahmadi O, De Vincentis A. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Res Sq 2024; (e-pub ahead of print)
25 Balakrishnan M, Patel P, Dunn-Valadez S. et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (01) 61-71.e15
26 Kang S, Moon MK, Kim W, Koo BK. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J Cachexia Sarcopenia Muscle 2020; 11 (05) 1232-1241
27 Hsieh YC, Joo SK, Koo BK, Lin HC, Kim W. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2021; 41 (03) 494-504
28 Caussy C, Tripathi A, Humphrey G. et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019; 10 (01) 1406
29 Loomba R, Seguritan V, Li W. et al. Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017; 25 (05) 1054-1062.e5
30 Wijarnpreecha K, Lou S, Watthanasuntorn K. et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020; 32 (05) 601-608
31 Wang B, Jiang X, Cao M. et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 2016; 6 (01) 32002
32 Lee G, You HJ, Bajaj JS. et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020; 11 (01) 4982
33 Lang S, Demir M, Martin A. et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology 2020; 159 (05) 1839-1852
34 Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol 2023; 79 (06) 1524-1541
35 Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther 2021; 38 (05) 2130-2158
36 Ingoe L, Phipps N, Armstrong G, Rajagopal A, Kamali F, Razvi S. Prevalence of treated hypothyroidism in the community: analysis from general practices in North-East England with implications for the United Kingdom. Clin Endocrinol (Oxf) 2017; 87 (06) 860-864
37 Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004; 30 (06) 498-505
38 Human Growth Hormone: Research and Clinical Practice. Springer Link. 2000. Accessed June 23, 2024 at: https://link.springer.com/book/10.1007/978-1-59259-015-5
39 Murray RD. The phenotype of adults with partial growth hormone deficiency. Horm Res 2005; 64 (Suppl. 02) 12-17
40 Sesti G, Sciacqua A, Cardellini M. et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005; 28 (01) 120-125
41 Hayes FJ, Fiad TM, McKenna TJ. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 1999; 48 (03) 308-313
42 Sesmilo G, Biller BM, Llevadot J. et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133 (02) 111-122
43 Li CH, Chou YT, Shen WC. et al. Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population. J Diabetes Investig 2020; 11 (05) 1336-1343
44 Oosthuyse T, Bosch AN. Oestrogen's regulation of fat metabolism during exercise and gender specific effects. Curr Opin Pharmacol 2012; 12 (03) 363-371
45 Lee C, Kim J, Jung Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cells 2019; 8 (10) 1259
46 Cerhan JR, Moore SC, Jacobs EJ. et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 2014; 89 (03) 335-345
47 Siren R, Eriksson JG, Vanhanen H. Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. BMC Public Health 2012; 12 (01) 631
48 Loomba R, Kayali Z, Noureddin M. et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 2018; 155 (05) 1463-1473.e6
49 Lawitz E, Poordad F, Coste A. et al. Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH. J Hepatol 2017; 1 (66) S34
50 Ratziu V, de Guevara L, Safadi R. et al; ARREST Investigator Study Group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021; 27 (10) 1825-1835
51 Loomba R, Mohseni R, Lucas KJ. et al. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology 2021; 161 (05) 1475-1486
52 Davison BA, Harrison SA, Cotter G. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol 2020; 73 (06) 1322-1332
53 Bedogni G, Bellentani S, Miglioli L. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
54 Lee JH, Kim D, Kim HJ. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42 (07) 503-508
55 Fennoun H, Mansouri SE, Tahiri M. et al. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. Pan Afr Med J 2020; 37: 270
56 Poynard T, Ratziu V, Naveau S. et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10
57 Hernaez R, Lazo M, Bonekamp S. et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54 (03) 1082-1090
58 Romero-Gómez M, Cortez-Pinto H. Detecting liver fat from viscoelasticity: how good is CAP in clinical practice? The need for universal cut-offs. J Hepatol 2017; 66 (05) 886-887
59 Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol 2019; 25 (11) 1307-1326
60 Coco B, Oliveri F, Maina AM. et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14 (05) 360-369
61 Millonig G, Reimann FM, Friedrich S. et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48 (05) 1718-1723
62 Hsu C, Caussy C, Imajo K. et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 2019; 17 (04) 630-637.e8
63 Imajo K, Kessoku T, Honda Y. et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016; 150 (03) 626-637.e7
64 Park CC, Nguyen P, Hernandez C. et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017; 152 (03) 598-607.e2
65 Yilmaz Y. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clin Chim Acta 2012; 413 (15–16): 1190-1193
66 Masarone M, Troisi J, Aglitti A. et al. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics 2021; 17 (02) 12
67 Kalhan SC, Guo L, Edmison J. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60 (03) 404-413
68 Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009; 50 (03) 574-585
69 Rodríguez-Suárez E, Duce AM, Caballería J. et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 2010; 4 (04) 362-371
70 Kwok R, Tse YK, Wong GLH. et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39 (03) 254-269
71 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014; 20 (31) 10851-10863
72 Ajmera V, Perito ER, Bass NM. et al; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017; 65 (01) 65-77
73 Feldstein AE, Lopez R, Tamimi TA. et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 51 (10) 3046-3054
74 Alkhouri N, Berk M, Yerian L. et al. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014; 59 (07) 1617-1624
75 Gorden DL, Myers DS, Ivanova PT. et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res 2015; 56 (03) 722-736
76 Asanuma T, Ono M, Kubota K. et al. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 2010; 59 (02) 258-266
77 Smits LP, Coolen BF, Panno MD. et al. Noninvasive differentiation between hepatic steatosis and steatohepatitis with MR imaging enhanced with USPIOs in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2016; 278 (03) 782-791
78 Bastati N, Feier D, Wibmer A. et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2014; 271 (03) 739-747
79 Stine JG, Munaganuru N, Barnard A. et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (11) 2274-2283.e5
80 Tamaki N, Munaganuru N, Jung J. et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 2022; 71 (05) 983-990
81 Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 2011; 11 (02) 103-106
82 Sterling RK, Lissen E, Clumeck N. et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (06) 1317-1325
83 Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43 (08) 617-649
84 Ampuero J, Pais R, Aller R. et al; HEPAmet Registry. Development and validation of Hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol 2020; 18 (01) 216-225.e5
85 Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E. et al. Hepamet fibrosis score in nonalcoholic fatty liver disease patients in Mexico: lower than expected positive predictive value. Dig Dis Sci 2021; 66 (12) 4501-4507
86 Vali Y, Lee J, Boursier J. et al; On Behalf Of The Litmus Systematic Review Team. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. J Clin Med 2021; 10 (11) 2415
87 Guha IN, Parkes J, Roderick P. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (02) 455-460
88 Nobili V, Parkes J, Bottazzo G. et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136 (01) 160-167
89 Vali Y, Lee J, Boursier J. et al; LITMUS Systematic Review Team(†). Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 2020; 73 (02) 252-262
90 Adams LA, George J, Bugianesi E. et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26 (10) 1536-1543
91 Bertot LC, Jeffrey GP, de Boer B. et al. Comparative accuracy of clinical fibrosis markers, Hepascore and Fibroscan® to detect advanced fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2023; 68 (06) 2757-2767
92 Harrison SA, Ratziu V, Boursier J. et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020; 5 (11) 970-985
93 Sanyal AJ, Shankar SS, Yates KP. et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med 2023; 29 (10) 2656-2664
94 Wilder J, Patel K. The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl) 2014; 7: 107-114
95 Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017; 66 (05) 1486-1501
96 Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging 2013; 94 (05) 515-534
97 Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. AJR Am J Roentgenol 2020; 214 (01) W20-W26
98 Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C. Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56 (06) 2125-2133
99 Loomba R, Wolfson T, Ang B. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60 (06) 1920-1928
100 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77 (05) 1797-1835
101 Singh S, Venkatesh SK, Wang Z. et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015; 13 (03) 440-451.e6
102 Venkatesh SK, Wang G, Teo LLS, Ang BWL. Magnetic resonance elastography of liver in healthy Asians: normal liver stiffness quantification and reproducibility assessment. J Magn Reson Imaging 2014; 39 (01) 1-8
103 Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2023; 165 (04) 1080-1088
104 Jung J, Loomba RR, Imajo K. et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021; 70 (10) 1946-1953
105 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol 2022; 76 (06) 1362-1378
106 Petta S, Vanni E, Bugianesi E. et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35 (05) 1566-1573
107 Loong TCW, Wei JL, Leung JCF. et al. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2017; 32 (07) 1363-1369
108 Anstee QM, Lawitz EJ, Alkhouri N. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR Trials. Hepatology 2019; 70 (05) 1521-1530
109 Inadomi C, Takahashi H, Ogawa Y. et al. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2020; 50 (06) 682-692
110 Shima T, Sakai K, Oya H. et al. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2020; 55 (01) 100-112
111 Cassinotto C, Boursier J, Paisant A. et al. Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD. Hepatology 2021; 73 (06) 2196-2205
112 Yamada H, Suzuki K, Ichino N. et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99-103
113 Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). MicroRNA 2018; 7 (03) 215-222
114 Yu F, Wang X, Zhao H, Hao Y, Wang W. Decreased serum miR-1296 may serve as an early biomarker for the diagnosis of non-alcoholic fatty liver disease. Clin Lab 2019; 65 (10)
115 Jiang H, Qian Y, Shen Z. et al. Circulating microRNA–135a–3p in serum extracellular vesicles as a potential biological marker of non–alcoholic fatty liver disease. Mol Med Rep 2021; 24 (01) 498
116 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6 (08) e23937
117 Pirola CJ, Fernández Gianotti T, Castaño GO. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64 (05) 800-812
118 Liu XL, Pan Q, Zhang RN. et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016; 22 (44) 9844-9852
119 López-Riera M, Conde I, Quintas G. et al. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep 2018; 8 (01) 10606
120 Younossi ZM, Blissett D, Blissett R. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64 (05) 1577-1586
121 Axley P, Ahmed Z, Arora S. et al. NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: a population-based study. Liver Transpl 2019; 25 (05) 695-705
122 Agopian VG, Kaldas FM, Hong JC. et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256 (04) 624-633
123 Wong VWS, Adams LA, de Lédinghen V, Wong GLH, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 2018; 15 (08) 461-478
124 Brunt EM. Liver biopsy reliability in clinical trials: thoughts from a liver pathologist. J Hepatol 2020; 73 (06) 1310-1312
125 Brunt EM, Clouston AD, Goodman Z. et al. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol 2022; 76 (05) 1030-1041